AstraZeneca is set to eliminate about 600 sales roles in the United States focused on respiratory and immunology products, according to reports cited by both outlets. The cuts are described as targeting sales representatives tied to those therapeutic areas.

Context is provided mainly through the shared reliance on Bloomberg News reporting. One outlet frames the move as “eliminating” sales representatives, while the other emphasizes that the jobs are being cut in the US. Beyond the headcount and the business area affected, neither provided summary includes details on the rationale, timing, or any company response in the information shown.

Overall, the difference across outlets appears limited to emphasis and wording, not to the core facts: a reduction of roughly 600 sales jobs, with a specific focus on respiratory and immunology, attributed to Bloomberg’s reporting.